Himal Lal1, Airi Poder2, Laura Campora3, Brecht Geeraerts4, Lidia Oostvogels5, Carline Vanden Abeele6, Thomas C Heineman7. 1. GSK, 709 Swedeland Road, King of Prussia, PA 19406, USA. Electronic address: himallal@yahoo.com. 2. Kliiniliste Uuringute Keskus, 54 Sobra, 50160 Tartu, Estonia. Electronic address: airi.poder@std.ee. 3. GSK, 20 Avenue Fleming, 1300 Wavre, Belgium. Electronic address: laura.e.campora@gsk.com. 4. GSK, 20 Avenue Fleming, 1300 Wavre, Belgium. Electronic address: brecht.r.geeraerts@gsk.com. 5. GSK, 20 Avenue Fleming, 1300 Wavre, Belgium. Electronic address: lidia.oostvogels@gsk.com. 6. GSK, 20 Avenue Fleming, 1300 Wavre, Belgium. Electronic address: carline.c.vanden-abeele@gsk.com. 7. GSK, 709 Swedeland Road, King of Prussia, PA 19406, USA. Electronic address: thomas.heineman@genocea.com.
Abstract
BACKGROUND: In phase III trials, 2 doses of a herpes zoster (HZ) subunit vaccine (HZ/su; 50 µg varicella-zoster virus glycoprotein E [gE] and AS01B Adjuvant System) administered 2-months apart in older adults (≥50 and ≥70 years) demonstrated >90% efficacy in preventing HZ and had a clinically acceptable safety profile. Here we report immunogenicity, reactogenicity and safety following administration of 2 HZ/su doses at intervals longer than 2 months. METHODS: In this Phase III, open-label trial conducted in the US and Estonia, 354 adults≥50 years were randomized 1:1:1 to receive 2 HZ/su doses 2, 6, or 12 months apart. gE-specific humoral immune responses were evaluated at pre-vaccination, 1 and 12 months post-dose 2. Co-primary objectives were to compare immune responses to HZ/su 1 month post-dose 2 when given 6-months or 12-months apart to those administered 2-months apart. For each participant, safety information was collected from dose 1 to 12 months post-dose 2. RESULTS:346 participants completed the study and 343 were included in the according-to-protocol cohort for immunogenicity. One month post-dose 2, vaccine response rates were 96.5% (97.5% confidence interval [CI]: 90.4; 99.2) and 94.5% (97.5% CI: 87.6; 98.3) for the 0, 6- and 0, 12-month schedules, respectively, both schedules meeting the pre-defined criterion. Non-inferiority of anti-gE geometric mean concentrations was demonstrated for HZ/su administered on 0, 6-month compared to a 0, 2-month schedule; however, HZ/su administered on a 0, 12-month schedule did not meet the non-inferiority criterion. Injection site pain was the most commonly reported solicited adverse event (AE). 26 participants each reported at least 1 serious AE; none were assessed as related to vaccination. CONCLUSIONS:Immune responses to HZ/su administered at 0, 6-month were non-inferior to those elicited by a 0, 2-month schedule. HZ/su exhibited a clinically acceptable safety profile for all dosing intervals. CLINICAL TRIALS REGISTRATION: Clinicaltrials.gov (NCT01751165).
RCT Entities:
BACKGROUND: In phase III trials, 2 doses of a herpes zoster (HZ) subunit vaccine (HZ/su; 50 µg varicella-zoster virus glycoprotein E [gE] and AS01B Adjuvant System) administered 2-months apart in older adults (≥50 and ≥70 years) demonstrated >90% efficacy in preventing HZ and had a clinically acceptable safety profile. Here we report immunogenicity, reactogenicity and safety following administration of 2 HZ/su doses at intervals longer than 2 months. METHODS: In this Phase III, open-label trial conducted in the US and Estonia, 354 adults ≥50 years were randomized 1:1:1 to receive 2 HZ/su doses 2, 6, or 12 months apart. gE-specific humoral immune responses were evaluated at pre-vaccination, 1 and 12 months post-dose 2. Co-primary objectives were to compare immune responses to HZ/su 1 month post-dose 2 when given 6-months or 12-months apart to those administered 2-months apart. For each participant, safety information was collected from dose 1 to 12 months post-dose 2. RESULTS: 346 participants completed the study and 343 were included in the according-to-protocol cohort for immunogenicity. One month post-dose 2, vaccine response rates were 96.5% (97.5% confidence interval [CI]: 90.4; 99.2) and 94.5% (97.5% CI: 87.6; 98.3) for the 0, 6- and 0, 12-month schedules, respectively, both schedules meeting the pre-defined criterion. Non-inferiority of anti-gE geometric mean concentrations was demonstrated for HZ/su administered on 0, 6-month compared to a 0, 2-month schedule; however, HZ/su administered on a 0, 12-month schedule did not meet the non-inferiority criterion. Injection site pain was the most commonly reported solicited adverse event (AE). 26 participants each reported at least 1 serious AE; none were assessed as related to vaccination. CONCLUSIONS: Immune responses to HZ/su administered at 0, 6-month were non-inferior to those elicited by a 0, 2-month schedule. HZ/su exhibited a clinically acceptable safety profile for all dosing intervals. CLINICAL TRIALS REGISTRATION: Clinicaltrials.gov (NCT01751165).
Authors: Abdulmohammad Pezeshki; Inna G Ovsyannikova; Brett A McKinney; Gregory A Poland; Richard B Kennedy Journal: Expert Rev Vaccines Date: 2019-02-11 Impact factor: 5.217
Authors: Anna Mz Gagliardi; Brenda Ng Andriolo; Maria Regina Torloni; Bernardo Go Soares; Juliana de Oliveira Gomes; Regis B Andriolo; Eduardo Canteiro Cruz Journal: Cochrane Database Syst Rev Date: 2019-11-07
Authors: Pieter T de Boer; Alies van Lier; Hester de Melker; Albert J M van Wijck; Jan C Wilschut; Albert Jan van Hoek; Maarten J Postma Journal: BMC Med Date: 2018-12-06 Impact factor: 8.775
Authors: Philip J M Brouwer; Mitch Brinkkemper; Pauline Maisonnasse; Nathalie Dereuddre-Bosquet; Marloes Grobben; Mathieu Claireaux; Marlon de Gast; Romain Marlin; Virginie Chesnais; Ségolène Diry; Joel D Allen; Yasunori Watanabe; Julia M Giezen; Gius Kerster; Hannah L Turner; Karlijn van der Straten; Cynthia A van der Linden; Yoann Aldon; Thibaut Naninck; Ilja Bontjer; Judith A Burger; Meliawati Poniman; Anna Z Mykytyn; Nisreen M A Okba; Edith E Schermer; Marielle J van Breemen; Rashmi Ravichandran; Tom G Caniels; Jelle van Schooten; Nidhal Kahlaoui; Vanessa Contreras; Julien Lemaître; Catherine Chapon; Raphaël Ho Tsong Fang; Julien Villaudy; Kwinten Sliepen; Yme U van der Velden; Bart L Haagmans; Godelieve J de Bree; Eric Ginoux; Andrew B Ward; Max Crispin; Neil P King; Sylvie van der Werf; Marit J van Gils; Roger Le Grand; Rogier W Sanders Journal: Cell Date: 2021-01-26 Impact factor: 41.582
Authors: Kathleen L Dooling; Angela Guo; Manisha Patel; Grace M Lee; Kelly Moore; Edward A Belongia; Rafael Harpaz Journal: MMWR Morb Mortal Wkly Rep Date: 2018-01-26 Impact factor: 17.586